Moleculin Biotech, Inc. — Form 8-K
Filed October 30, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Moleculin Biotech completed dosing of 90 patients in Part A of its Phase 2/3 MIRACLE trial evaluating Annamycin + cytarabine for relapsed/refractory AML. The company rebalanced the patient population to a ~50/50 split between those who failed 7+3 chemotherapy versus venetoclax-based regimens (versus prior 70/30 split across first 45 subjects). Comprehensive Part A data readout remains scheduled for Q1 2027 to support dose selection for Part B; no specific dollar amounts, share counts, or counterparties are disclosed in this filing.
Why this rating
Phase 3 trial progress milestone for microcap biotech; represents ~1-2 year advancement toward potential regulatory pathway. Critical for clinical validation but execution risk remains high; financing not secured.
See more from October 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.